| abstract |
R1 and R2 are each independently a hydrogen, -OH, alkyl, -CF 3, -OCHF 2, -OCF 3 or halogen; R3 is cycloalkyl, -OCH 2 CF 3, -OCH 2 CHF 2, -OCH 2 CH 2 F or CH 2 OCH 3, and; R4 is hydrogen, -OH, -O aryl, -OCH 2 aryl, alkyl, cycloalkyl, -CF 3, -OCHF 2, -OCF 3, -OCH 2 CF 3, -OCH 2 CHF 2, -OCH 2 CH 2 F or halogen; A is -CX 1 X 2 wherein X 1 And X 2 are each independently H, F and Cl, and when X 1 and X 2 are both H, then R 3 is -OCH 2 CH 3 , or a pharmaceutically acceptable salt, solvate, polymorph , Enantiomers or racemic mixtures are disclosed. The compounds have inhibitor activity of sodium-dependent glucose transport proteins. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the compounds, use of the compounds and pharmaceutical compositions in the treatment of diseases associated with the manufacture of medicaments of SGLT2 inhibitors. |